An NCI-designated Comprehensive Cancer Center
Diane Prager

Diane J. Prager, M.D.

Medical Oncologist
Appointments
Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research
Diane J. Prager, M.D. is a board-certified oncologist who is “passionate about patient care with tailored smart solutions.” She is excited about the promise of precision, targeted therapies and especially immunotherapy (“the next wave!” she exclaims).
 
Educated in South Africa, Dr. Prager received her medical degree from Johannesburg’s University of the Witwatersrand and continued her training at Johannesburg University Hospitals, followed by residency and fellowship at Cedars Sinai Medical Center and UCLA in Los Angeles. She directed UCLA’s lung cancer program from 2000 to 2005.
 
After 14 years in private practice in Peoria, Illinois, Dr. Prager returns to Southern California to join City of Hope, which she calls a “center of excellence.”

Locations

City of Hope South Bay
5215 Torrance Blvd

Torrance, CA 90503

  • Cella D, Herbst R, Lynch TJ, Prager D, et al. Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients with Non-Small Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled Trial. J Clin Oncol 23(13), May 1, 2005. PMID: 15699477
  • Herbst R, Prager D, Hermann R, et al. TRIBUTE – A phase III trial of erlotinib HCL combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 23(25):5892-9, September 1, 2005. PMID: 16043829
  • Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, Prager D, Monberg MJ, Ye Z, Obasaju CK. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol. 2006 Oct 20;24(30):4840-7. PMID: 17050869
  • Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 2007 Sep 20;25(27):4270-7. PMID: 17878479
  • Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager D, Stella PJ, Rowland KM Jr, Novotny PJ, Loprinzi CL. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011 Jan 1;29(1):97-105. Epub 2010 Nov 22. PMID: 21098317
  • Crawford J, Swanson P, Schwarzenberger P, Sandler A, Prager D, Zhang K, Freeman DJ, Johnson CW, Krishnan K, Johnson D. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2013 Dec;8(12):1510-8. PMID: 24389433
  • Ma W-W, Karapetis C, Balcke P, Kennecke H, Stahi M, Milella M, Martin JL, Nugent FW, Prager D, Lu B, Ferrara S, Penenberg D, Van Hoff DD. Influence of primary pancreatic tumor location on efficacy and safety in a phase III Trial (IMPACT)of nab-paclitaxel (nab-P) plus gemcitibine (Gem) vs Gem alone for patients with metastatic pancreatic cancer (PC). Annals of Oncol 2014; 25(suppl_4):iv210-iv253.10.1093/annonc/mdu334
  • Prager D, Muir J, Miller L, et al. SmartCare at a Community Cancer Center. J Clin Oncol. 2015; 33(15) _ suppl.e17535
In The News